NCT04554485View on ClinicalTrials.gov

Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Lymphoblastic Leukemia, Acute, AdultPh Negative ALLNewly Diagnosed
Interventions
DRUG

Blinatumomab

Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults

Trial Locations (5)

12800

Institute of Hematology and Blood Transfusion, Czech Republic, Prague

50005

University Hospital Hradec Kralove,The 4th Department of Internal Medicine - Hematology, Hradec Králové

60200

University Hospital Brno, Internal hematology and oncology clinic, Brno

70852

University Hospital Ostrava, Hematooncology Clinic, Ostrava

77900

University Hospital Olomouc, Hematooncology Clinic, Olomouc

All Listed Sponsors
collaborator

CZECRIN - Czech Clinical Research Infrastructure Network

UNKNOWN

lead

Institute of Hematology and Blood Transfusion, Czech Republic

OTHER

NCT04554485 - Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL) | Biotech Hunter | Biotech Hunter